PR Newswire
17 Apr 2023, 04:30 GMT+10
![]() |
BANGALORE, India and DELAWARE CITY, Del. and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.
The eight posters highlight data from the microbiological and efficacy studies of the clinical candidate, BWC0977 that exhibits broad-spectrum activity against a globally, diverse panel of Gram-positive, Gram-negative and biothreat pathogens. Additionally, data from a range of studies, including in vitro biochemical assays, in vitro resistance frequency studies, minimum inhibitory concentration (MIC90) data against multi-drug resistant clinical isolates from around the world, and in vivo efficacy data in mice and rat models of infection will be presented.
These studies were conducted in collaboration with scientists at the Walter Reed Army Institute of Research (WRAIR), Bethesda, USA, University of Liverpool, United Kingdom, University of Texas Medical Branch, USA, International Health Management Associates (IHMA), USA and TheraIndx Lifesciences Pvt. Ltd., India.
"ECCMID 2023 is a globally renowned platform in Infectious Diseases R&D arena, and we are proud to have the opportunity to showcase the pre-clinical highlights of our drug candidate BWC0977; a first-of-its-kind in over six decades that has the potential to treat an entire gamut of infections caused by hard-to-treat Gram-negative and Gram-positive bacterial pathogens," says Dr. Vasanthi Ramachandran, Vice President - Collaborations, Bugworks Research India.
Bugworks Research is at the forefront of developing novel antibiotics to combat the growing threat of antimicrobial resistance. The company's cutting-edge research is focused on discovering and developing small molecule drugs that target bacterial enzymes essential for their survival.
The ECCMID conference is a leading global forum for infectious diseases and clinical microbiology. Bugworks Research's presentations will take place on April 13th, 2023, during the poster session. Attendees are invited to visit the Bugworks Research booth to learn more about the company's innovative approach to fighting antibiotic resistance.
About Bugworks
Bugworks Research Inc, (Bugworks), is a clinical stage biopharmaceutical company, that is developing novel multi target therapeutic assets in the anti-infectives and immuno-oncology (IO) areas by integrating the latest innovations in computational biology, pharmacology, structural-biology, and medicinal chemistry. BWC0977 is currently in a Phase 1 clinical trial and is targeted to address unmet needs of serious hospital & community infections, and bacterial biothreats. Its asset for IO is in the late pre-clinical stage, targets multiple cancers and is expected to be used either as standalone or in combination with immune checkpoint therapies.
For further information, please visit www.bugworksresearch.com
Media Contact Information
Concept Public Relations
Archana Jain ([email protected] / +91 98455 41244)
Aditi Nair ([email protected] / +91 9071949810)
Get a daily dose of Philippine Times news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Philippine Times.
More InformationMOSCOW, Russia - Russia came to a standstill on Friday as the nation commemorated its victory over Nazi Germany in the second World...
DHAKA, Bangladesh: Thousands of supporters of the Islamist group Hefazat-e-Islam took to the streets of Dhaka to protest proposed legal...
Pope Leo XIV, has spoken publicly for the first time since his election as Pope to succeed Pope Francis who died on Easter Monday....
The EU on Wednesday called on India and Pakistan to take immediate steps' to de-escalate after India fired missiles into Pakistani-administered...
WASHINGTON, D.C.: President Donald Trump's administration is planning to cut many jobs at the CIA and other U.S. spy agencies, according...
BOISE, Idaho: Seven people died, and eight were hurt when a van carrying tourists crashed into a pickup truck and caught fire near...
SAN FRANCISCO, California: A U.S. lawmaker wants to introduce a new law that would help track where advanced AI computer chips, like...
EAST HARTFORD, Connecticut: Roughly 3,000 members of the International Association of Machinists and Aerospace Workers began striking...
CHICAGO, Illinois: United Airlines will begin canceling around 35 daily flights—roughly 10 percent of its schedule—from Newark Liberty...
NEW YORK, New York - U.S. stocks rose sharply Thursday following the announcement by U.S. President Donald Trump of a new trade deal...
WASHINGTON, D.C.: Dozens of major footwear companies, including Nike, Adidas, and Skechers, have signed a letter urging U.S. President...
IRVING, Texas: Kimberly-Clark, the maker of Kleenex tissues and Huggies diapers, announced this week it will invest US$2 billion over...